CLIAC April 2018: Topic Discussion Questions and Background Information



<u>Implementation of Next Generation Sequencing in Public Health and Clinical Laboratories</u>

Discussion Questions for CLIAC Consideration:

- 1. What major gaps and issues do laboratories experience when implementing NGS-based testing for various applications?
- 2. What guidance is lacking for laboratories that perform NGS testing to address critical steps in the total testing process?
- 3. How can CDC, CMS, and FDA assist in filling NGS-related gaps and providing guidance to laboratories?

Clinical Laboratory Workforce

Discussion Questions for CLIAC Consideration:

- 1. How do we best assess workforce development needs and the gaps in meeting them?
- 2. How can CDC, CMS, and FDA assist in filling needs in the areas of workforce development and training?

Background Information:

Workforce Shortage CLIAC Summary
 https://ftp.cdc.gov/pub/CLIAC meeting presentations/pdf/Addenda/cliac0418/9a Workforce Shortage CLIAC Summary 03292018.pdf

Laboratory Interoperability

Discussion Questions for CLIAC Consideration:

- 1. What challenges remain for achieving semantic interoperability?
- 2. How can CMS, FDA, and CDC facilitate addressing those challenges?
- 3. How can CMS, FDA and CDC support industry in their efforts to provide standard test codes for laboratories?
- 4. What incentives would laboratories need to voluntarily implement the laboratory data exchange standards? (HL7, LOINC, SNOMED, UCUM, LIVD)

Background Information:

- CLIAC Recommendations Interoperability
 https://ftp.cdc.gov/pub/CLIAC meeting presentations/pdf/Addenda/cliac0418/12a CLIAC Recommendations I nteroperability.pdf
- 2. Laboratory Interoperability Discussions
 https://ftp.cdc.gov/pub/CLIAC_meeting_presentations/pdf/Addenda/cliac0418/12b_Laboratory%20Interoperability%20Discussions_04052018.pdf
- 3. IICC LAW and LIVD Handout https://ftp.cdc.gov/pub/CLIAC meeting presentations/pdf/Addenda/cliac0418/15a IICC LAW and LIVD Hand out.pdf
- 4. Interoperability LIVD Example https://ftp.cdc.gov/pub/CLIAC_meeting_presentations/pdf/Addenda/cliac0418/15b_Heierman_Interoperability_LIVDExcelDigitalFormatExample.pdf

Using Clinical Laboratory Data to Improve Quality and Laboratory Medicine Practices

Discussion Questions for CLIAC Consideration:

- 1. What areas of health care have had quality transformed by big data? What were the metrics of success and lessons learned?
- 2. How can clinical laboratory data be used effectively to identify quality-related issues and provide evidence to demonstrate the value of the laboratory?
- 3. What are the challenges in using laboratory data for these purposes?
- 4. How can CDC, CMS, and FDA guide and support HHS policies that encourage such use of clinical laboratory and pathology data?

Background Information:

- Sawhney S, Fraser SD. Epidemiology of AKI: Utilizing Large Databases to Determine the Burden of AKI. Advances in Chronic Kidney Disease. 2017;24(4):194-204. doi:10.1053/j.ackd.2017.05.001. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648688/
- 2. Siew ED, Basu RK, Wunsch H, et al. Optimizing administrative datasets to examine acute kidney injury in the era of big data: workgroup statement from the 15th ADQI Consensus Conference. *Canadian Journal of Kidney Health and Disease*. 2016;3:12. doi:10.1186/s40697-016-0098-5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768415/
- 3. Sutherland S, M, Goldstein S, L, Bagshaw S, M, Leveraging Big Data and Electronic Health Records to Enhance Novel Approaches to Acute Kidney Injury Research and Care. Blood Purif 2017;44:68-76. https://www.karger.com/Article/Pdf/458751
- 4. Mehta R, Bihorac A, Selby NM, et al. Establishing a continuum of acute kidney injury tracing AKI using data source linkage and long-term follow-up: Workgroup Statements from the 15th ADQI Consensus Conference. Canadian Journal of Kidney Health and Disease. 2016;3:13. doi:10.1186/s40697-016-0102-0. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768419/pdf/40697 2016 Article 102.pdf